CTLA4 and sarcoma: Recently, in mouse models of sarcoma and colon cancer, propranolol reduced tumor angiogenesis, increased T cell infiltration, and reduced myeloid-derived suppressor cell infiltration, leading to an up-regulation of PD-L1 on tumor-associated macrophages, ultimately enhancing the efficacy of anti-CTLA4 therapy (33).